Skip to main content
Premium Trial:

Request an Annual Quote

Richard Woychik, Tom Vasicek, Holly Marcum, Cesar Collado, Jim Hauske, Joseph Turgeon, Mary Holland, David Macdonald, Regina Herzlinger, A. Blaine Bowman, Richard Morris

Premium

Richard Woychik will leave his position as chief scientific officer of Lynx Therapeutics in August to become director of The Jackson Laboratory, Lynx said last week. Woychik also joins Lynx’ board of directors.

Lynx also said last week that it has chosen Tom Vasicek to become vice president of business development, where he will lead business-development efforts for Lynx’s MPSS and Protein ProFiler technologies. Prior to joining Lynx, Vasicek was previously chief scientific officer at LabSeek Scientific Collaborative. In previous positions, Vasicek served as director of commercial technology for Corning’s Advanced Life Sciences Products division, and as a manager of DNA microarray application development at Millennium Pharmaceuticals.

 

Chemical genomics company Amphora Discovery has hired two additional members for its management team: Holly Marcum, a former senior director of corporate development for Incyte Genomics, will be executive director of business development and commercialization. Cesar Collado, a former business development executive at Eli Lilly, joins as vice president of business development and commercialization. Amphora is based in Research Triangle Park, NC.

 

Jim Hauske will join Beyond Genomics as chief scientific officer, the company said last week. In his new position, which was previously unfilled, Hauske will lead the company’s systems biology-based drug discovery efforts and expand the research team. Prior to joining BG, Hauske served as senior vice president of discovery for Sepracor, where he led the company’s efforts to develop novel therapeutics. In previous positions, Hauske worked for over 15 years at Pfizer, where he held research positions and contributed to the development of azithromycin.

 

Nanogen has hired Joseph Turgeon as its new vice president of operations and Mary Holland as its senior director of worldwide corporate accounts. Prior to joining Nanogen, Turgeon served as vice president of operations at Progeny Systems and Medical Electronics Systems of San Diego, the same companies which Nanogen’s new senior vice president of operations, David Macdonald, formerly headed. Turgeon was also director of operations at the Nichols Institute, a subsidiary of Quest Diagnostics.

Holland comes to Nanogen from Third Wave Technologies, where she served in senior sales and marketing positions for seven years and was also a co-founder of Oncogenetics, a genetics and cancer diagnostics research laboratory.

Nanogen also recently announced that Regina Herzlinger has stepped down from her position on the company’s board of directors.

 

Microtransponder array startup PharmaSeq of Monmouth Junction, NJ, appointed A. Blaine Bowman and Richard Morris to its board of directors. Bowman is president and CEO of Dionex, the ion chromatography company that recently made a $3 million investment in PharmaSeq. Morris is the CEO of PharmaSeq, and joined the company in January.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.